Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Combination immunotherapy shows over 50% long-term disease control in melanoma patients with brain metastases.

flag A new study shows that a combination of immunotherapy drugs can significantly improve survival rates for melanoma patients with cancer that has spread to the brain. flag The seven-year follow-up of a clinical trial revealed that over 50% of patients treated with this combination achieved long-term disease control. flag This is a major improvement from the previous 16-week survival rate. flag The study, published in the Lancet Oncology, suggests that combination immunotherapy should become the standard treatment for such patients.

15 Articles

Further Reading